Učitavanje...
A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer
Trastuzumab is the standard treatment in Canada for patients with breast cancer positive for her2 (human epidermal growth factor receptor 2), dramatically improving outcomes in that patient group. However, its current intravenous (IV) administration is associated with long infusion times that place...
Spremljeno u:
| Izdano u: | Curr Oncol |
|---|---|
| Glavni autori: | , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Multimed Inc.
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6380645/ https://ncbi.nlm.nih.gov/pubmed/30853812 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.26.4220 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|